Recordati Industria Chimica e Farmaceutica Dirección
Dirección controles de criterios 3/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Rob Koremans
Chief Executive Officer (CEO)
€2.2m
Compensación total
| Porcentaje del salario del CEO | 27.4% |
| Permanencia del CEO | 2.3yrs |
| Participación del CEO | n/a |
| Permanencia media de la dirección | 3.4yrs |
| Promedio de permanencia en la Junta Directiva | 4.6yrs |
Actualizaciones recientes de la dirección
Recent updates
Recordati Industria Chimica e Farmaceutica's (BIT:REC) Dividend Will Be Increased To €0.63
Apr 25
Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Share Price Could Signal Some Risk
Apr 23If EPS Growth Is Important To You, Recordati Industria Chimica e Farmaceutica (BIT:REC) Presents An Opportunity
Apr 08Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.63
Mar 23Is Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 27We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt
Jan 09Risks To Shareholder Returns Are Elevated At These Prices For Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 22Recordati Industria Chimica e Farmaceutica (BIT:REC) Has Announced That It Will Be Increasing Its Dividend To €0.57
Nov 12Is Recordati Industria Chimica e Farmaceutica (BIT:REC) Using Too Much Debt?
Sep 29Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 08Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Jun 23Does This Valuation Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Imply Investors Are Overpaying?
Jun 05Recordati Industria Chimica e Farmaceutica's (BIT:REC) Conservative Accounting Might Explain Soft Earnings
Apr 08Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.60
Apr 05Recordati Industria Chimica e Farmaceutica (BIT:REC) Has Announced That It Will Be Increasing Its Dividend To €0.60
Mar 19Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Mar 06A Look At The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 23Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?
Dec 05Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.55
Nov 11Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Intrinsic Value Is Potentially 42% Above Its Share Price
Sep 01These 4 Measures Indicate That Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Using Debt Reasonably Well
Aug 07An Intrinsic Calculation For Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Suggests It's 25% Undervalued
Jun 03Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Paying Out A Larger Dividend Than Last Year
May 16Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Paying Out A Larger Dividend Than Last Year
May 02Recordati Industria Chimica e Farmaceutica's (BIT:REC) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 18Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.57
Apr 04Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.57
Mar 21These 4 Measures Indicate That Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Using Debt Reasonably Well
Mar 06Calculating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 22Recordati Industria Chimica e Farmaceutica (BIT:REC) Has A Pretty Healthy Balance Sheet
Dec 05Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 23Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?
Sep 05A Look At The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Jun 25Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Jun 07Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 8.5% And Analysts Are Revising Their Forecasts
May 10Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Shares Could Be 34% Above Their Intrinsic Value Estimate
Mar 11Here's What You Should Know About Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) 2.4% Dividend Yield
Feb 19Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Jan 30Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | €389m |
| Sep 30 2023 | n/a | n/a | €375m |
| Jun 30 2023 | n/a | n/a | €389m |
| Mar 31 2023 | n/a | n/a | €340m |
| Dec 31 2022 | €2m | €590k | €312m |
| Sep 30 2022 | n/a | n/a | €331m |
| Jun 30 2022 | n/a | n/a | €330m |
| Mar 31 2022 | n/a | n/a | €393m |
| Dec 31 2021 | €154k | n/a | €386m |
Compensación vs. Mercado: La compensación total de Rob($USD2.31M) está por debajo de la media de empresas de tamaño similar en el mercado Italian ($USD3.92M).
Compensación vs. Ingresos: La compensación de Rob ha aumentado más de un 20% en el último año.
CEO
Rob Koremans (61 yo)
2.3yrs
Permanencia
€2,154,000
Compensación
Dr. Robert Koremans, also known as Rob, M.D. serves as Chief Executive Officer and Director of Recordati Industria Chimica e Farmaceutica S.p.A. since December 1, 2021. Dr. Koremans served as Chief Executi...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | €2.15m | sin datos | |
| Group CFO & Executive Director | 4.4yrs | €1.11m | sin datos | |
| Executive Director | no data | sin datos | sin datos | |
| Executive Director | no data | sin datos | sin datos | |
| Executive Director | no data | sin datos | sin datos | |
| VP & Head of Investor Relations | less than a year | sin datos | sin datos | |
| Group Chief Legal Officer | less than a year | sin datos | sin datos | |
| Group Communications Director | no data | sin datos | sin datos | |
| Executive VP of Corporate Development | 7.6yrs | sin datos | sin datos | |
| Group Chief People & Culture Officer | less than a year | sin datos | sin datos | |
| Executive Vice President of Group Industrial Operations | 9yrs | sin datos | sin datos | |
| Chief Medical Officer | 5.3yrs | sin datos | sin datos |
3.4yrs
Permanencia media
54yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de REC se considera experimentado (3.4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | €2.15m | sin datos | |
| Group CFO & Executive Director | 2.3yrs | €1.11m | sin datos | |
| Executive Director | 5.3yrs | sin datos | sin datos | |
| Executive Director | 5.3yrs | sin datos | sin datos | |
| Executive Director | 4yrs | sin datos | sin datos | |
| Non-Executive Chairman | 26yrs | €352.00k | sin datos | |
| Independent Non-Executive Director | 4yrs | €77.00k | sin datos | |
| Lead Independent Director | 10yrs | €98.00k | sin datos | |
| Independent Director | 2.3yrs | €61.00k | sin datos | |
| Chairman of Statutory Auditor Board | 7yrs | sin datos | sin datos | |
| Independent Non-Executive Director | 5.2yrs | €82.00k | sin datos | |
| Non-Executive Vice Chairman | 4yrs | €60.00k | sin datos |
4.6yrs
Permanencia media
53.5yo
Promedio de edad
Junta con experiencia: La junta directiva de REC se considera experimentada (4.6 años de antigüedad promedio).